Moderna today presented Phase I data showing that its closely-watched messenger RNA (mRNA) COVID-19 vaccine candidate mRNA-1273 showed immunogenicity in patients 55 years old and older that was roughly the same or higher than data seen in younger patients at the dosage the company is using in its Phase III trial.
Moderna’s series of two 100 mcg doses of mRNA-1273 seroconverted all 120 participants in a Phase I trial (NCT04283461) after the first dose given on Day 1, with the area under the curve for all age groups exceeding the median of convalescent sera, Jacqueline M. Miller, MD, FAAP, Moderna’s senior VP of infectious disease development, stated during a presentation at the August meeting of the CDC Advisory Committee on Immunization Practices (ACIP).
The presentation included Moderna’s first release of detailed data on mRNA-1273 in patients older than age 55.
After the second dose was administered on Day 29, S-2P binding antibodies were seen in all age groups at levels equivalent to high-titer convalescent sera, Miller added. Moderna also reported geometric mean titer (GMT) levels of 267 for the 18–55 year old cohort, 324 for the 56–70 year old cohort,…
This News From Feed news.google title “Moderna COVID-19 Vaccine Shows Immunogenicity in Older Patients – Genetic Engineering & Biotechnology News”
geico insurance,instant auto insurance quote,get auto insurance online,purchase auto insurance online,auto insurance quotes online,farmers insurance,farm insurance,a car insurance